‘Sprinkle’ Method of Giving Kadian Capsules Approved

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WILMINGTON, Del-The FDA has cleared an alternative method of administration of the pellets contained in Zeneca’s Kadian (morphine sulfate sustained release) capsules.

WILMINGTON, Del—The FDA has cleared an alternative method of administration of the pellets contained in Zeneca’s Kadian (morphine sulfate sustained release) capsules.

Rather than being swallowed whole, now the capsules may be opened and the entire contents sprinkled on a small amount of applesauce immediately prior to ingestion. The pellets should not be chewed, crushed, or dissolved due to risk of overdose, the company said.

In a study of healthy volunteers, Kadian pellets sprinkled over applesauce were found to be bioequivalent to Kadian capsules swallowed whole with apple-sauce under fasting conditions. With the sprinkle administration, patients should consume the entire portion and should not divide the applesauce into separate doses. Other foods for use with Kadian pellets have not been tested in patients.

Kadian is prescribed for the management of moderate-to-severe chronic pain when treatment with an opioid analgesic is indicated for more than a few days.

“The recent approval of Kadian in sprinkle-supplement form allows patients who experience moderate-to-severe pain, and have difficulty swallowing capsules or tablets, 24-hour pain control with the option of a single dose,” said oncologist Robert Kerr, MD, of Southwest Regional Cancer Center, Austin, Tex.

Recent Videos
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Related Content